.jpg)
With 40 years of manufacturing expertise and 30 years of regulatory experience, we supply leading separation, purification and extraction technologies to support chromatography and biocatalysis applications in healthcare and life sciences.
(目前只有英文)
Purolite is a leading manufacturer of synthetic and agarose-based resins used in the bioprocessing, pharmaceutical, nutraceutical and medical device industries.
Whether in separation, extraction or purification, our innovative solutions and unmatched technical support place us at the forefront of the global Healthcare & Life Sciences marketplace.
We understand complex Pharma regulatory environments and can ensure security of supply, which keeps our customers confident that their products will reach the market with accuracy and speed.
-0876.jpg/jcr:content/Purolite_Laboratory(HR)-0876-min.jpg)
Monoclonal antibody (mAb) therapeutics are widely used to treat ailments including cancer, rheumattoid arthritis, demntia and diabetes. Agarose based chromatography resins are a vital technology for biopharmaceutical developers to obtain optimal purity in downstream mAb bioprocessing.
These devices assist patients around the world in managing ailments such as liver and kidney failure, cystic fibrosis, metabolic deficiencies, dementia, diabetes, immunodeficiencies and many more. Chromatography and biocatalysis resins are utilized in many medical devices for treatment and diagnostic applications.
The nutraceutical industry extracts the nourishing parts of food to be used as over the counter medicine. As many people lack the necessary nutrients in their diet, the nutraceutical industry offers access to almost every nutrient needed. If someone is deficient in certain nutrient, a nutritional supplement is usually available.
Purolite has been manufacturing and selling to the generic pharmaceutical market for over three decades. Generics are off-patent drugs that are bioequivalent to branded medications in terms of dosage, strength, quality, form, effect, intended use, side effects, and route of administration. The generic market in the US alone will approach $200 billion by 2024 and is having a positive impact on lowering the cost of health care.
